Carboplatin Use in Neoadjuvant Pembrolizumab Regimens for Triple-Negative Breast Cancer

Standard Regimen for Stage II/III TNBC

• The American Society of Clinical Oncology recommends the KEYNOTE-522 protocol, which includes 4 cycles of AC or EC + pembrolizumab, for stage II/III triple-negative breast cancer patients, with a hazard ratio of 0.63 (95% CI 0.48-0.82, P<0.001) for event-free survival compared to chemotherapy alone 1, 2

When Carboplatin is Routinely Indicated

• The European Society for Medical Oncology suggests that carboplatin should be standard for all stage II and III triple-negative breast cancer patients receiving neoadjuvant pembrolizumab, with a benefit independent of germline BRCA1/2 status 1, 2
• The National Comprehensive Cancer Network recommends carboplatin for node-positive disease at presentation, with recent studies showing reduced risk of recurrence with regimens that incorporate carboplatin in addition to pembrolizumab-based regimen 2, 3

Key Evidence Supporting Routine Carboplatin Use

• The St. Gallen 2023 consensus states that some panelists favor inclusion of carboplatin in neoadjuvant therapy for TNBC, particularly if used in node-positive cancers and in conjunction with pembrolizumab-based treatment, with a pathological complete response rate of 64.8% with pembrolizumab-chemotherapy versus 51.2% with chemotherapy alone 2, 3

Pembrolizumab Use Independent of PD-L1

• The American Society of Clinical Oncology recommends pembrolizumab regardless of PD-L1 status, with the benefit from pembrolizumab being independent of PD-L1 expression, and testing for PD-L1 not required to determine eligibility for pembrolizumab in early TNBC 1, 2

Alternative Considerations (When Carboplatin Might Be Omitted)

• The European Society for Medical Oncology suggests that carboplatin may potentially be omitted only in stage I T1a or T1b disease where chemotherapy itself is being used selectively, or in patients with contraindications to platinum therapy 3, 4

Critical Implementation Points

• The National Comprehensive Cancer Network recommends adjuvant pembrolizumab continuation regardless of pathologic response (pCR or residual disease), with a sequence that uses paclitaxel-carboplatin-pembrolizumab first, followed by anthracycline-cyclophosphamide-pembrolizumab 1, 2, 3

Neoadjuvant Therapy for Triple-Negative Breast Cancer

Standard Approach and Rationale

• The American Society of Clinical Oncology recommends neoadjuvant therapy as the standard approach for treating patients with stage II and III early triple-negative breast cancer (TNBC) 5, 6
• This approach allows for effective downstaging of tumors for surgical purposes, assessment of pathologic complete response (pCR), and opportunity to tailor adjuvant therapy based on response 5, 7
• The assessment of pathologic complete response (pCR) remains a strong prognostic factor regardless of germline BRCA1/2 status 5

Recommended Regimens for Stage II/III TNBC

• The National Comprehensive Cancer Network recommends the KN522 trial protocol: chemotherapy with taxanes, carboplatin, anthracyclines, cyclophosphamide, combined with concurrent pembrolizumab as the preferred neoadjuvant regimen for stage II/III triple-negative breast cancer 5, 7, 6
• The benefit from pembrolizumab is independent of PD-L1 status 5
• Anthracycline-based regimens followed by taxanes are an evidence-based sequential therapy option 5, 8

Post-Neoadjuvant Therapy

• The European Society for Medical Oncology recommends that for patients with residual disease after standard neoadjuvant chemotherapy, consider adjuvant capecitabine for six to eight cycles if germline BRCA1/2 wild-type 9
• Regardless of the extent of response to neoadjuvant chemotherapy plus pembrolizumab, ongoing adjuvant pembrolizumab is favored 5

Stage-Specific Recommendations

• For Stage I TNBC, consider adding carboplatin and pembrolizumab for higher-risk stage I disease 5
• For Stage II TNBC, AC/T chemotherapy is recommended, with consideration of adding pembrolizumab for cT2 cN0 9
• For Stage III TNBC, AC/T chemotherapy with pembrolizumab is recommended, with neoadjuvant therapy strongly preferred 9

Neoadjuvant Therapy for Triple-Negative Breast Cancer

Rationale for Regimen Selection

• The National Comprehensive Cancer Network (NCCN) 2024 guidelines designate dose-dense AC followed by weekly paclitaxel as a "preferred regimen" (Category 1) for triple-negative breast cancer in the neoadjuvant setting, with a strength of evidence of Category 1 10
• Weekly paclitaxel demonstrates superior disease-free survival compared to every-3-week paclitaxel (HR 1.27, 95% CI 1.03-1.57, P=0.006) 10
• The NCCN recommends carboplatin primarily for node-positive disease or in conjunction with pembrolizumab-based regimens, but not for cT2N0 (node-negative) triple-negative breast cancer 10

Critical Modifications for Comorbidities

• Cyclophosphamide is acceptable in stage 3 CKD but requires adequate hydration monitoring 10
• Doxorubicin cumulative dose should not exceed 240 mg/m² (4 cycles at 60 mg/m²) 10
• Elderly patients (≥65 years) experience more severe myelosuppression with standard regimens, requiring close monitoring 11
• Dose-dense regimens with growth factor support are appropriate and maintain efficacy in older adults 10

Specific Treatment Protocol

• Paclitaxel 80 mg/m² IV over 3 hours weekly for 12 consecutive weeks 10
• Doxorubicin 60 mg/m² IV + Cyclophosphamide 600 mg/m² IV every 2 weeks for 4 cycles with G-CSF support 10
• Administer G-CSF (filgrastim or pegfilgrastim) starting 24-72 hours after each AC cycle 10

Monitoring and Supportive Care

• Hemoglobin A1c monthly to assess diabetes control during treatment 11
• Weekly assessment during paclitaxel phase using patient-reported outcomes to monitor neuropathy 10

Expected Outcomes and Surgery Timing

• Pathological complete response rates with AC followed by weekly paclitaxel range from 31-41% in triple-negative breast cancer 10, 12
• Surgery should be scheduled 3-4 weeks after final chemotherapy cycle to allow count recovery 10